Dexcel Pharma Technologies Ltd., 10% Owner at Urovant Sciences Ltd. (UROV), bought 13,298 shares at $7.97 ($106K) on 2019-06-07, disclosed to the SEC on 2019-06-11.
Scheduled purchase ($106k) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.97 | 6,649 | $53K | 50.0% |
| 2 | $7.97 | 6,649 | $53K | 50.0% |
| Total | $7.97 avg | 13,298 | $106K | 100% |
| Filing → |
| UROV | BUY | 2019-06-19 | $262K | — | Filing → |
| UROV | BUY | 2019-06-14 | $355K | — | Filing → |
| MYOV | BUY | 2019-06-06 | $40.0M | — | Filing → |